Pipeline
Treg Targeted Biologics for Immune-Mediated Diseases
Our pipeline of large molecules reflects TRexBio’s commitment to creating fit-for-purpose therapeutics with a focus on the tissue – where disease presents – offering new potential for safer, more effective, and more durable control of immune-mediated diseases. We have both wholly owned and partnered assets.
Atopic Dermatitis
TRB-061
- Preclinical
- IND Enabling
- Phase 1
- Phase 2
- Phase 3
TRB-061 is a novel TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRB-061 is in clinical development for moderate-to-severe atopic dermatitis (AD).
IMMUNOLOGY
TRB-071
- Preclinical
- IND Enabling
- Phase 1
- Phase 2
- Phase 3
TRB-071 is an investigational CD30 agonist designed to both augment tissue Tregs and block an immune system inflammatory pathway. Genetic studies support the involvement of CD30 and its ligand in inflammatory bowel disease. TRB-071 is currently in IND-enabling studies.
IMMUNOLOGY
TRB-051
Partner: Lilly
- Preclinical
- IND Enabling
- Phase 1
- Phase 2
- Phase 3
Our Collaborations
Separate from our pipeline of wholly owned programs, we have collaborated with leading biopharma and academic partners to accelerate the discovery and development of novel immunology programs. Our partnership with Eli Lilly includes two programs, TRB-041 and TRB-051, identified and advanced using TRexBio’s Deep Biology Platform. We also partnered with Johnson & Johnson Innovative Medicine to explore new targets in immunology and inflammation.
